

PRELIB

CENTRE D'AUTO-PRÉLÈVEMENT

Prelib: evaluating a newly launched Canadian provider of innovative internet-based services for self-directed HIV and STI screening

Dr. Maxim R-Éthier & Dr. Khadija Benomar
Friday, May 1, 2020



Canadian Association for
HIV Research
L'association canadienne de
recherche sur le VIH


Disclosures

- Gilead
- Merck
- Viiv

BACKGROUND

- STI rates are going up in Quebec
- Technology-enabled screening services
 - Promising class of interventions
 - Improving testing uptake
 - Addressing barriers to testing
- Prelib
 - New clinic downtown Montreal
 - Accessible, convenient and judgement-free STI screening services
 - Combining internet-based risk assessment with on-site self-sampling

SCREENING PROCESS



OBJECTIVE OF THE STUDY

- *To evaluate the uptake, feasibility and acceptability of Prélib STI screening services overall*

METHODS

- Observational data span
 - December 1, 2018 (launch) to October 11, 2019
- Self-reported data entered on the online patient portal
 - Demographic and risk factor database
- Electronic medical records
 - Laboratory tests ordered and results
 - Chlamydia trachomatis (CT)
 - Neisseria gonorrhoeae (NG)
 - Syphilis
 - Hepatitis B (HBV)
 - Hepatitis C (HCV)
 - HIV

RESULTS

- Among 1317 profiles: 69,0% attended first appointment
- Completion rate for each step was over 75%

Among 909 appointment attendees

- Median age was **29.0**
 - [IQR= 24.0-36.0]
- Mean number of partners in the past 2 months was **2.8** [median : 2]
- **22.2%** were men who have sex with men
- **73.8%** reported unprotected sex in the pas 3 months
- **23.4%** reported first-time screening
- **STI prevalence** was **6.6%**, driven by NG and CT
- No HIV infection

USER CHARACTERISTICS


CHARACTERISTIC	ATTENDEES (N=909)
History of injection drug use N (%)	2 (0.2%)
History of sex work N (%)	12 (1.3%)
Current use of PrEP N (%)	43 (4.7%)
Past STI diagnosis N (%)	235 (25.9%)
First-time tester N (%)	213 (23.4%)

STI PREVALENCE

	N / N TESTED	PREVALENCE (%)
Any STI	56 / 849	6.6%
CT (any)	29 / 836	3.5%
CT (urogenital)	22 / 834	2.6%
CT (anal swab)	9 / 177	5.1%
NG (any)	23 / 837	2.7%
NG (urogenital)	7 / 834	0.8%
NG (any extragenital)	19 / 540	3.5%
NG (anal swab)	6 / 177	3.4%
NG (oral swab)	16 / 539	3.0%
Syphilis	7 / 812	0.9%
HBV	1 / 388	0.3%
HCV (anti-HCV)	1 / 256	0.4%
HIV	0 / 808	0.0%

CONCLUSION

Prélib demonstrated **feasibility** and **acceptability** following launch, based on high screening completion rates and STI prevalence comparable to local clinical practice, and reached many high-risk and first-time testers.



QUESTIONS ?

maxim.ethier@prelib.com
khadija.benomar@prelib.com